Abicipar pegol for treating wet age-related macular degeneration [ID1533]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 December 2024
Brolucizumab for treating wet age-related macular degeneration (TA672)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
Faricimab for treating wet age-related macular degeneration (TA800)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 November 2026
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 August 2008
TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC